Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel. [electronic resource]
Producer: 20210802Description: 3049-3063 p. digitalISSN:- 1838-7640
- Amino Acid Sequence
- Animals
- Antineoplastic Agents -- administration & dosage
- Ascites -- etiology
- B7-H1 Antigen -- biosynthesis
- Benzylamines -- administration & dosage
- Calcium-Calmodulin-Dependent Protein Kinase Type 2 -- antagonists & inhibitors
- Cellular Reprogramming Techniques
- Drug Compounding
- Drug Screening Assays, Antitumor
- Female
- Hydrogels -- administration & dosage
- Immunotherapy -- methods
- Injections, Intraperitoneal
- Liver Neoplasms, Experimental -- complications
- Macrophage Activation
- Male
- Melanoma, Experimental -- immunology
- Melitten -- administration & dosage
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Molecular Targeted Therapy -- methods
- Neoplasm Proteins -- antagonists & inhibitors
- Oligopeptides -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Random Allocation
- Recombinant Fusion Proteins -- administration & dosage
- Sulfonamides -- administration & dosage
- Tumor Escape -- drug effects
- Tumor-Associated Macrophages -- classification
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.